Science at a Glance
Quick, digestible excerpts from the latest scientific breakthroughs and wellness insights, curated for your longevity journey.
Ozempic Face Is Real — Here's What's Happening to Your Skin
A growing body of scientific research confirms that "Ozempic face" — the noticeable facial aging seen in people taking GLP-1 weight-loss medications like Ozempic and Wegovy — is a real and measurable phenomenon. A 2025 imaging study found that patients lost an average of 7% of their midfacial volume for every 10 kg (22 lbs) of weight lost, with the most visible thinning occurring in the superficial fat layers just beneath the skin. A large database study also found that patients on these medications were significantly more likely to develop drooping eyelids and sagging skin around the eyes — and were more likely to seek cosmetic procedures like eyelid surgery and facelifts. This effect goes beyond simply losing weight: the fat changes in the face appear more pronounced than what would be expected from weight loss alone.
Scientists have also uncovered why this happens at a cellular level. GLP-1 medications appear to directly affect the stem cells and structural cells in facial fat and skin — reducing their ability to produce collagen, increasing oxidative damage, and even lowering local estrogen levels that normally keep skin firm. In essence, these drugs may be accelerating facial skin aging through multiple biological pathways, not just shrinking fat. The good news: dermatologists and plastic surgeons are developing targeted treatments to address this, including fat grafting (reinjecting the patient’s own fat to restore volume and stem cells), specialized fillers, and radiofrequency skin-tightening procedures — with early results showing high patient satisfaction. While “Ozempic face” is not officially listed as a side effect on drug labels, it is increasingly recognized by medical professionals as a real consequence worth discussing with patients before starting these medications.
The Role of NAD+ in Cellular Repair
NAD+ (nicotinamide adenine dinucleotide) is a molecule found in every cell of the body, playing a vital role in energy production, DNA repair, and overall cellular health. As we age, NAD+ levels naturally decline, and researchers now believe this drop contributes to many hallmarks of aging — from reduced energy and slower tissue repair to increased vulnerability to disease. One of NAD+'s most important jobs is fueling enzymes called PARPs, which act like a cellular repair crew, patching up DNA damage caused by everyday stressors like UV radiation and oxidative stress. When DNA damage piles up, these repair enzymes can burn through NAD+ reserves faster than cells can replenish them, creating a damaging cycle where the very process meant to protect cells ends up depleting the fuel needed to keep them running.
To counter this, scientists have been studying supplements called NAD+ precursors — most notably nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — which the body can convert into NAD+. Recent human studies from 2023–2024 confirm these supplements can safely raise NAD+ levels in blood and tissues, with early trials showing encouraging results including better muscle insulin sensitivity, lower blood pressure, and reduced inflammation. Some of the most exciting findings come from studies on rare premature aging diseases, where NAD+ supplementation noticeably improved DNA repair and mitochondrial function. That said, the science isn't settled: human results have been more modest than what animal studies predicted, and key questions around ideal dosing, treatment duration, and who benefits most remain unanswered. Even the gut microbiome appears to influence how well these supplements are absorbed, adding another layer of complexity. Researchers are calling for larger, well-designed clinical trials before broad therapeutic recommendations can be made.
Advanced Lipid Testing for Heart Health
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in the blood that has emerged as one of the most significant independent risk factors for heart disease — yet most people have never had it tested. A landmark 2024 study published in the Journal of the American College of Cardiology pooled data from five major U.S. cohorts, tracking more than 20,000 participants across multiple ethnicities for over two decades. The findings were striking: people with Lp(a) levels in the top 10% faced a 66% higher risk of heart attack and a 68% higher risk of needing cardiac procedures compared to those with lower levels. Critically, this elevated risk held up regardless of sex, race, ethnicity, or whether LDL cholesterol (the traditional "bad cholesterol") was already well-controlled — even in patients with LDL levels as low as 70 mg/dL. The risk was especially pronounced in people with diabetes. These results directly informed the National Lipid Association's 2024 recommendation that all adults be screened for Lp(a) at least once in their lifetime.
The evidence doesn't stop there. Massive independent datasets reinforce the same conclusion. The UK Biobank, with over 400,000 participants, and the BiomarCaRE project, spanning nearly 57,000 people across seven European cohorts, both found consistent, dose-dependent relationships between rising Lp(a) levels and cardiovascular events across all groups studied. Perhaps most practically compelling, research from the Copenhagen studies found that adding Lp(a) to standard risk assessments correctly reclassified 23% of heart attack cases into higher-risk categories — without mistakenly downgrading anyone's risk. In plain terms, testing for Lp(a) catches people at serious cardiovascular risk who would otherwise fly under the radar of conventional cholesterol screening, making a strong case for its routine use in preventive care.
Circadian Rhythms & Metabolism
The body's internal clock — known as the circadian rhythm — does far more than govern sleep and wakefulness. It orchestrates a vast network of metabolic processes, and when that clock falls out of sync with daily behavior, the consequences for cardiometabolic health can be significant. A landmark 2024 American Heart Association Scientific Statement published in Circulation representing the first major guideline-level synthesis of this field, concluded that circadian disruption meaningfully impairs glucose tolerance, insulin sensitivity, and lipid metabolism. Controlled human studies put hard numbers to this: just 3.5 days of circadian misalignment — mimicking a shift work schedule — reduced skeletal muscle insulin sensitivity by roughly 22%, while separate research showed that the body's natural evening dip in glucose tolerance stems from a 27% reduction in early-phase insulin secretion from the pancreas. These aren't just laboratory curiosities; the same molecular clock genes that regulate sleep also control cholesterol synthesis, inflammation, and even the timing of cardiovascular events like heart attacks.
What makes this research especially actionable is the role of meal timing. When and how long we eat turns out to matter independently of how many calories we consume. Food acts as a powerful time signal for metabolic organs — essentially resetting peripheral clocks in the liver, muscle, and pancreas regardless of light exposure. A 2024 meta-analysis in JAMA Network Open found that time-restricted eating (confining food intake to an 8–12 hour daily window) produced measurable improvements in weight, waist circumference, blood sugar control, and fasting glucose. Eating earlier in the day, when insulin sensitivity is naturally at its peak, appears to offer the greatest metabolic benefit, while late-night eating is associated with increased risk of obesity, type 2 diabetes, and cardiovascular disease. The AHA's statement frames circadian alignment — through consistent sleep timing, strategic light exposure, and well-timed meals and physical activity — as a genuinely promising and underutilized tool for disease prevention.
Neurobiology of Deep Sleep Cycles
Not all sleep is created equal. While total sleep duration matters, emerging research points to a specific stage — deep slow-wave sleep (SWS) — as particularly critical for long-term brain health. A landmark 2023 study in JAMA Neurology, drawing on 17 years of follow-up data from the Framingham Heart Study, found that each percentage-point decline in slow-wave sleep per year was associated with a 27% increase in dementia risk — and people who went on to develop dementia experienced roughly twice the rate of slow-wave sleep loss as those who stayed cognitively healthy. The reason appears rooted in a recently discovered brain cleaning system: during deep sleep, slow rhythmic changes in brain blood flow drive cerebrospinal fluid through neural tissue, flushing out toxic proteins like amyloid-β and tau that are hallmarks of Alzheimer's disease. Perhaps most remarkably, slow-wave sleep also appears to function as a form of cognitive reserve — in people who already carry significant amyloid buildup in their brains, stronger slow-wave activity was independently associated with better memory function, even after accounting for education and physical activity levels.
When it comes to sleep duration, the relationship with dementia risk follows a U-shaped curve, with seven hours per night emerging as the apparent sweet spot. Consistently sleeping six hours or fewer during midlife is linked to a 30% higher dementia risk, while sleeping nine or more hours carries even stronger associations — up to a 77% increased risk for all-cause dementia, though researchers note that excessive sleep may sometimes reflect early neurodegeneration rather than cause it. Sleep quality matters just as much as quantity: poor sleep, fragmented sleep, and insomnia symptoms each independently raise dementia risk by anywhere from 13% to over 50% depending on severity. A 2025 analysis of more than 313,000 UK Biobank participants found that people with the most severely disrupted sleep patterns faced up to 85% higher dementia risk overall and a 56% increased risk of Alzheimer's specifically. The encouraging takeaway is that unlike fixed risk factors such as genetics or years of education, sleep is modifiable — and optimizing it, especially during midlife, represents one of the most accessible levers available for protecting long-term brain health.